New! View global litigation for patent families

US3290117A - Occult blood diagnostic composition with color enhancing agent - Google Patents

Occult blood diagnostic composition with color enhancing agent Download PDF

Info

Publication number
US3290117A
US3290117A US29025363A US3290117A US 3290117 A US3290117 A US 3290117A US 29025363 A US29025363 A US 29025363A US 3290117 A US3290117 A US 3290117A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
agent
blood
hydroperoxide
indicator
mg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Jr Ernest Clarence Adams
Haitsma Cornelia Theodora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • G01N33/725Haemoglobin using peroxidative activity

Description

United States Patent 3,290,117 OCCULT BLOOD DIAGNOSTIC COMPOSITION WITH COLOR ENHANCING AGENT Ernest Clarence Adams, Jr., and Cornelia Theodora Haitsma, Elkhart, Ind., assignors to Miles Laboratories, Inc.,' Elkhart, Ind., a corporation of Indiana No Drawing. Filed June 24, 1963, Ser. No. 290,253 18 Claims. (Cl. 23-253) This invention relates to an improved diagnostic composition and to a method for its preparation. Particularly, this invention is concerned with a diagnostic test which is useful for the qualitative detection and quantitative determination of blood in body fluids and products of elimination such as urine, vomitus, gastro-intestinal contents, cerebrospinal fluids and feces. In particular, this invention is concerned with a highly sensitive reagent composition for the detection of occult blood which may be incorporated upon a bibulous carrier..

The detection of occult blood in body fluids and body excreta has become an invaluable aid to the medical practitioner in the diagnosis of a great number of abnormal conditions. Medical science has long recognized a need for and the usefulness of a test for occult blood. Hence it is considered extremely desirable to provide a simple and economical test for the qualitative detection and quantitative determination of occult blood in body fluids and body excreta.

Blood is found in the gastric contents and in vomitus in conditions associated with erosion of gastric and intestinal mucuous membranes and, for example, ulcerous and carcinogenic conditions. In the feces, the regular and frequent occurrence of occult blood is suggestive of, for example, gastro-intestinal cancer, gastric or duodenal ulcers or hemorrhoids. Quite often, hemorrhage is so slight that it is no possible to detect the presence of blood by microscopic examination. Hence, a sensitive and specific diagnostic test for occult blood. is highly desirable. In the urine, the presence of blood cells or blood pigments may be indicative of a number of abnormal conditions, for example, typhus, scurvy, purpura, pyemia, nephritis, third degree burns, carcinogenic conditions of the urinary system, and as a result of the action of various hemolytic toxins and the like. In accordance with this invention, a simple and economical diagnostic test composition is provided which may advantageously be used with ease by hospital and clinical personnel untrained in laboratory technique as well .as the skilled laboratory technician and physician.

A variety of techniques, reagents, and devices have been used or proposed in the past for the detection of occult blood in body fluids and body excreta, for example, U.S. Patent 2,290,436 to Jonas Ka-mlet, issued. July 21, 1942; U.S. Patent 2,799,660 to Richard S. Nicholls and Dale E. Fonner, issued July 16, 1957; U.S. Patent 2,838,377 to Dale E. Fonner, issued June 10, 1958; U.S. Patent 3,012,976 to Ernest C. Adams, In, and James A. Peterson, issued December 12, 1961; and U.S. Patents 3,092,463 and 3,092,464 to Ernest C. Adams, ]r., and James Peterson, issued June 4, 1963, all assigned to the instant assignee.

The inventive concept of the instant application, as that of the prior art, is based on the catalytic activity of the prosthetic groups present in blood. The catalytically active substances identified. in hemoglobin belong to the general class of hemoproteins, conjugate proteins, all of which have the same prosthetic groups, iron protoporphyrin or heme. This prosthetic group has the ability to catalyze the oxidation of certain compounds by peroxides such as hydrogen peroxide, metal peroxides and organic peroxides. If the compound is an indicator or dye pre 3,290,117 Patented Dec. 6, 1966 cursor, colorless until it becomes oxidized and colored in its oxidized form, then the presence of the catalytic activity and hence the presence of blood is indicated by color formation. The rapidity of the color change and the depth or density of the color when compared to a set of standards is a means of the quantitative estimation of the blood present.

In accordance with this invention, we have discovered that the color formation in the presence of blood utilizing reagent compositions comprising an indicator and peroxide is unexpectedly enhanced by the addition of a quinoline derivative to each of the various blood detecting compositions. The quinoline derivatives found to be satisiactory as potentiating agents in the formulation of this where R may be hydrogen, methyl or hydroxy; R may be hydrogen, methyl or thiophenyl; R may be hydrogen or methyl or the substituted quinuclidine radical,

(J CHITI-CH OH (11112 CH2 which is common to quinine and cinchonine; R may be hydrogen, methyl or methoxy; R may be hydrogen or methyl and R may be hydrogen, methyl hydroxy or amino. Quinolines substituted in the 4, 6 or 7 position together with quinoline itself and quinine form a preferred subgroup of potentiating agents. By way of specific examples, suitable potentiat-ing agents include quinoline; quinine; cinchonine; 6-methoxyquinoline; 4,6-dimethylquinoline; 6-methylquinoline; 7-methylquinoline; 2,6-dimethylquinoline; Z-methylquinoline (quinaldine); 8- amino-6-methoxyquinoline; 6-methoxy-3-phenylthioquino-' line; 8-methylquinoline; 2,3-dimethylquinoline 2-quinolinol; 2-methyl-8-quinolinol and 8-quino'1-r'nol.

As suggested above, each of the occult blood tests aforementioned may be improved by the addition of the quinoline or substituted quinoline potentiating agent. For example the potentiating agent may be mixed with the dry compositions or tablets of U.S. Patent 2,290,436 to produce a diagnostic composition having greater sensitivity than the mixture of indicator peroxide and acidic material disclosed in the patent. In another respect, the tablets disclosed in U.S. Patent 2,799,660 comprising indicator peroxide buffer and effervescent couple and color contrast agent may be similarly improved by use of the potentiating agents of this invention. The blood test of U.S. Patent 2,838,377 comprising an indicator, a peroxide and a bufier incorporated in a closed envelope formed of an electrolyte permeable sheet material may be similarly improved by the utilization of one or more of the various potentiating agents described above.

The occult blood tests described in U.S. Patent 3,012,- 976 comprise an organic hydroperoxide, an indicator and a buffer and may be improved by the inclusion therein of the potentiating agent of the instant invention. The encapsulated compositions of U.S. Patent 3,092,463 may be likewise improved by use of a potentiating agent of the quinoline type. Likewise the organic hydroperoxides of U.S. 3,092,464 are similarly improved.

In an especially preferred embodiment of this invention, a group of organic hydroperoxides having pronounced sensitivity in an indicator reaction may be encapsulated or entrapped with a colloidal material such as gelatin and the gelatin hardened by fixing with a dialdehyde polysaccharide. The addition of -a buffer and a suitable indi cator as well as a potentiating agent of the quinoline or substituted quinoline family completes the formulation which results in an extremely sensitive diagnostic test reagent for occult blood.

The compositions of this invention may be prepared in solution or tablet form or may be used to impregnate a bibulous material such as paper, wood, fiber or the like, having any desired size or shape. Such products will undergo a distinct color change when contacted with an occult blood-containing specimen.

The group of organic hydroperoxides mentioned above which have been found to have the pronounced sensitivity which is required for the indicator reaction to be utilized in the diagnostic compositions of this invention comprise a group of materials including cu-mene hydroperoxide; diisopropylbenzene hydroperoxide; paramethane hydroperoxide; and 2,5-dimethy-lhexane, 2,5-dihydroperoxide; to mention a few of the significant members of this group. Other organic hydroperoxides of similar structure may likewise be used if desired.

Organic hydroperoxides, while producing outstanding results in various occult blood diagnostic compositions, have been found to be relatively unstable when mixed with the various other materials which are required in the provision of diagnostic compositions of this nature. In accordance with the co-pending application of Ernest C. Adams, Jr., and Norman R. Novak, S.N. 107,646, filed May 4, 1961, a novel encapsulating material is provide-d for the organic hydroperoxide. This encapsulating material may be comprised of various protein or polysaccharide materials such as gelatin, algin, carrageenin, casein, albumin or other materials of this nature. These proteinaceous or 'polysaccharous materials are applied to the test compositions and then hardened by means of a fixing process which involves treating with a dialdehyde polysa-ccharide which is effective for this purpose.

By way of example of buffering systems useful in the composition of this invention are tartrate, phosphate, phthalate, citrate and acetate buffer. The preferred range of hydrogen ion concentration to which the composition is buifered is about pH 4 to pH 7.

A pointed out above, the encapsulating material to be used in the diagnostic compositions of this invention is fixed or hardened by treatment with a dialdehyde polysaccharide. Dialdehyde polysaccharides sometimes known as periodate oxidized polysaccharides, for example, dialdehyde starch, may be prepared by the well-known oxidation of polysaccharides with periodic acid. This preparation is illustrated by the conversion of starch to dialdehyde starch using periodic acid as the oxidizing agent in accordance with the below set-out equation wherein x stands for the number of repeating units in a molecule which may range from 20 to several thousand.

OHzOH CHzOH hyde polysaccharides are used which are from about 50% to oxidized, that is, in the case of dialdehyde starch, those wherein 50 to 100 per 100 of the original anhydroglucose units have been converted to dialdehyde units such as by periodate oxidation.

In accordance with this invention, the dialdehyde polysaccharide is used in the form of an aqueous dispersion which may be readily prepared by adding the dialdehyde polysaccharide in the desired concentration, usually from about 0.25% to about 1.5%, to tap water or to a buffer solution and then mixing the aqueous dispersion with warming until a relatively homogenous dispersion is obtained. The dialdehyde polysaccharide may be used in whatever concentration is required to satisfactorily harden the encapsulating material to provide the desired stability features. The precise concentration to be used will be pointed out more particularly hereafter.

In the preparation of the compositions of this inven tion, it has been found desirable but not essential to mix the organic hydroperoxide being used with an emulsifying agent, for example, acacia mucilage, to form a primary emulsion. Other emulsifying agents which may be used include polyvinyl alcohol, gum arabic, carboxy vinyl polymer, and the like. A surfactant, or wetting agent, may also be used. In the preferred embodiment sodium lauryl sulfate is used as a wetting agent, however, dioctyl sodium sulfosuccinate for example is also satisfactory. An emulsifying agent when used serves to lower the surface tension of the oily organic hydroperoxide and forms a film around each individual oil droplet. The surfactant assists in this regard and, in addition, produces an even diffusion of color on the diagnostic stick. The resulting primary emulsion is buffered by means of an'appropriate buffer as discussed hereinabove. Preferably, the buffer in dilute form is first mixed with the material which is to form the capsule for the organic peroxide, for example, gelatin, before addition to the hydroperoxide emulsion. If the concentrated buffer is used with the encapsulating agent there is a tendency to precipitate the encapsulating agent prior to completion of the encapsulation. After the organic hydroperoxide has been entrapped or encapsulated, the concentrated buifer is added which has the effect of setting the encapsulation while controlling the pH and preventing false positives in testing. An aqueous dispersion of the dialdehyde polysaccharide is next added to serve as a fixing agent for the encapsulating material. The encapsulation material which is present in the film around the oily organic hydroperoxide droplets is thereby fixed by the dialdehyde polysaccharide, resulting in a more stable preparation.

It should be noted that thorough mixing is of extreme importance after each addition. This is particularly so upon the addition of the buffer-encapsulation mixture to the primary emulsion of the organic hydroperoxide. The addition of a suitable surfactant or wetting agent aids in the formation of a stable composition. The indicator, potentiating agent and organic solvent are mixed and then added to the hydroperoxide composition.

Although orthotolidine is the preferred indicator for the diagnostic compositions of this invention, various other indicator materials may be used so long as they satisfy the requirements pointed out above, namely, that they undergo a color change in the presence of an oxygen source and the blood for which the unknown material is being tested. Such indicators comprise a variety of organic materials, principally those of aniline and phenol derivation. T 0 name but a few, there may be used in addition to orthotolidine, orthotoluidine, paratoluidine, orthophenylenediamine, N,N' dimethyl-p-phenylenediamine, N,N'-diethyl-p-phenylenediamine, benzidine, panisidine, di-anisidine, o-cresol, m-cresol, p-cresol, alphanaphthol, beta-naphthol, catechol, guaiacol and pyrogallol.

As discussed hereinbefore, numerous substituted quinolines may be used as the potentiating agent in the testing compositions of this invention. In the preferred embodiment, however, quinoline itself or quinolines substituted in the 4-, 6- or 7-positions are used. Because of availability, economic reasons, and suitable physical properties, quinine has been found quite useful.

Among the organic solvents found useful in the composition and methods of this invention are chloroform, ethylene dichloride, benzene and ethyl acetate.

The novel compositions of this invention may' be prepared in tablet form, a convenient tablet size being about /8" thick and about A" in diameter. In determining the presence or absence of occult blood present in a specimen, a drop of the material to be tested (in the case of fecesan aqueous suspension of the specimen) is placed on a piece of dry filter paper and when the drop has soaked into thepaper, a reagent tablet is placed in the center of the drop and activated by the adition of two drops of water to the tablet. With a positive test, a ring of color appears on the filter paper surrounding the tablet, the color intensity varying, dependent upon the concentration of blood in the specimen. The color developed is then compared with a calibrated color chart to determine the concentration.

Alternatively, the dry composition may be added to a specific amount of water and mixed with the material to be tested. In the presence of occult blood, a color will be obtained. An estimation of the amount of occult blood present in the specimen may be made by comparing the color developed with calibrated standards.

It has been found that incorporating the compositions upon discs or strips of paper, small sticks of wood or other bibulous materials produces a most useful and sat isfactory diagnostic aid. In use, an impregnated strip is simply dipped in the liquid specimen or suspension of the material to be tested. In the presence of occult blood, the test strip will give a positive color reaction. The color resulting on the strip is then compared with precalibrated color standards for an estimation of the quantitative amount of occult blood contained in the specimen. The color developed in the presence of occult blood varies in intensity according to the amount of blood present. From a commercial point of view, test compositions in the form of bibulous sticks or strips are highly preferred because such provide the diagnostician with a simple dip and read test.

The range of compositions of the diagnostic material provided by this invention may vary within fairly wide limits in accordance with the general teachings set forth above.

The following examples will illustrate the improved diagnostic compositions of the present invention and method of preparing, the scope of the invention not, however, being limited to the specific details of these examples.

EXAMPLE 1 Hydroperoxide solution-40 grams of gum arabic were dissolved in 100 ml. of boiling water. To 100 ml. of this solution held at a temperature above 60 C. was added 5 ml. of cumene hydroperoxide and the mixture stirred for 5 minutes. 700 mg.gelatin was dissolved in 50 ml. of Buffer I (217.7 g. sodium citrate plus 49.2 g. citric acid made to 2 liters with H and added to the cumene hydroperoxide mixture. Both solutions were above 60 C. After thorough mixing, 1 ml. of 1% dialdehyde starch was added and mixed. Ten ml. of sodium lauryl sulfate was added and mixed. The resulting mixture was homogenized and allowed to cool to room temperature.

6 50 ml. of Buffer II (489.0 g. sodium citrate plus 111.0 g. citric acid plus 1% liters water) was then added with mixing.

Indicator soluti0n.400 mg. orthotolidine base and 10 mg. quinine alkaloid were dissolved in 20 ml. chloroform.

EXAMPLE 2 A hydroperoxide solution was prepared as in Example 1.

lndicat0r.--Prepared by dissolving 400 mg. o-tolidine base, 10 mg. quinine alkaloid and 12 mg. polyoxyethylenenonylphenol in 20 ml. chloroform.

EXAMPLES 3 and 4 The testing reagents were prepared in accordance with Example 1, the quinine alkaloid ingredient being increased to 20 mg. and 50 mg. per 20 ml. respectively.

EXAMPLES 5 and 6 The hydroperoxide solution was prepared in accordance with that of Example 2, the indicator solution was prepared containing 2 mg. polyoxyethylenenonylphenol and 20 mg. and 50 mg. quinine alkaloid per 20 ml. respectively.

EXAMPLE 7 The hydroperoxide solution was prepared in accordance with that of Example 1. The indicator solution was prepared to contain mg. o-tolidine, 10 mg. quinine alkaloid and 2 mg. polyoxyethylenenonylphenol per 20 ml. chloroform.

EXAMPLE 8 A hydroperoxide solution was prepared in accordance with that of Example 1. The indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 6-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.

EXAMPLE 9 A hydroperoxide solution was prepared in accordance wtih that of Example 1. The indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 6-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 mg.

EXAMPLE 10 A hydroperoxide solution was prepared in accordance with that of Example 1. The indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 7-methylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.

EXAMPLE 1 1 A hydroperoxide solution was prepared in accordance with that of Example 1. The indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 4,6-dimethylquinoline and 2 mg. polyoxyethylenenonylphenol per 20 ml.

EXAMPLE 12 A hydroperoxide solution was prepared in accordance with that of Example 1. The indicator solution was prepared to contain 80 mg. o-tolidine, 5 mg. 2,6-dimethylquinoline and 2 mg. polyoxyethylenenonylphenol.

EXAMPLE 13 amount of o-tolidine in the formulation for the reason that o-tolidine is less soluble in benzene than in chloroform or ethylene dichloride. While it is not essential, it was unexpectedly discovered by observation under ultraviolet light that the addition of a surface-active agent, for example, polyoxyethylenenonylphenol, to the indicator solution resulted in a more even application of the color indicator and quinine alkaloid when prepared in a strip or stick form. It was found that the amount of surfaceactive agent could be varied over a range between 1 and 20 mg. per 20 ml., the preferred amount being in the lower end of the range.

Preparation of reagent strips Bibulous sticks, that is, absorbent paper out into narrow strips having dimensions of about 3" x /5" x 0.029, were dipped into the hydroperoxide solution followed by drying in a drying tunnel at a temperature of about 100 C. The dried strips were subsequently heated in an oven at 70 C. for 8 to 16 hours to remove excess cumene hydroperoxide. The strips were similarly dipped into the indicator solution and dried in a 70 C. oven or a 50 C. drying tunnel. The finished impregnated strips were white to cream in color.

By way of illustration of the increased sensitivity of the test reagents of this invention, Table 1 sets out the results of 114 urine examinations from hospitalized patients, comparing the improved diagnostic test of this invention with prior known formulations.

TAB LE 1 Number Composition Applicants of Urines Cells per High Without Po Improved in Classi- Power Field tentiating Testing Comfication Agent position 62 Occasional 1 55 negatives 48 negatives 4 traces 5 traces 3 small 7 small 2 moderate 26 1-5 19 negatives 10 negatives 2 traces 1 trace 4 small 8 small 1 moderate 6 moderate 1 large 11 5-10 5 negatives 1 negative trace trace 2 small 3 small 4 moderate 4 moderate large 7 1020 3 negatives negative 1 trace 0 trace 2 small 3 small 1 moderate 4 moderate 8 20-50 2 negatives 0 negative 2 traces trace 2 small 3 small 2 moderate 3 moderate 2 large EXAMPLE 14 Benzidine method To 2 ml. of urine add 3 ml. saturated benzidine in glacial acetic acid (4 .g.O ml.) add 1 ml. of 3% hydrogen peroxide mix. A green to blue color indicates a positive reaction.

2 mg. of quinine were added to the above described method. A faster and more intense color was obtained.

2 mg. of 6-methoxyquinoline were added. This also made the color more intense but not as much as did the quinine.

Similar results have been obtained utilizing each of the potentiating agents described above.

It will be clearly understood by those skilled in the art that certain changes may be made in the above compositions and methods without departing from the spirit and scope of the invention and it is intended that all matter contained in the foregoing description shall be interpreted as illustrative and not in a limiting sense. It is also understood that other modifications may be made without departing from the spirit and scope of the appended claims.

What is claimed is:

1. A composition for detecting occult blood in body fluids and excreta comprising an organic hydroperoxide, a buffer capable of maintaining the pH of the material being tested within the range of about 4 to 7, gelatin and as a fixative for said gelatin a dialdehyde polysaccharide, an indicator capable of being oxidized in the presence of the prosthetic group of hemoglobin with an accompany color change and a potentiating agent of the formula OH2OHCHCH=CH2 R is a member selected from the group consisting of hydrogen, methyl and methoxy; R is a member selected from the group consisting of hydrogen and methyl; and R is a member selected from the group consisting of hydrogen, hy'droxy, methyl and amino.

2. The composition of claim 1 wherein the potentiating agent is quinine.

3. The composition of claim 1 wherein the potentiating agent is 6-methoxyquinoline.

4. The composition of claim 1 wherein the potentiating agent is 6-methyl quinoline.

5. The composition of claim 1 wherein the potentiating agent is 7-methyl quinoline.

6. The composition of claim 1 wherein the potentiating agent is 4,6-dimethyl quinoline.

7. The composition of claim 1 ing agent is quinoline.

8. The composition of claim 1 wherein the organic hydroperoxide is a member selected from the group consisting of cumene hydroperoxide, diisopropylbenzene hydroperoxide, paramenthane hydroperoxide and 2,5-dimethylhexane-2,5-dihydroperoxide.

9. A composition for detecting blood which comprises an indicator capable of being oxidized in the presence of the prosthetic group of hemoglobin with an accompanying color change, an oxidizing agent effective to oxidize said indicator and a potentiating agent of the formula wherein the potentiatthiophenyl; R is a member selected from the group consisting of hydrogen, methyl and the radical E R is a member selected from the group consisting of hydrogen, methyl and methoxy; R is a member selected from the group consisting of hydrogen and methyl; and R is a member selected from the group consisting of hydrogen, hydroxy, methyl and amino.

10. A composition according to claim 9 wherein the potentiating agent is a member selected from the group consisting of quinine, 6-methoxyquinoline, 6-methyl quinoline, 7-methyl quinoline, 4,6-dimethyl quinoline and quinoline.

11. A test indicator for detecting occult blood in body fluids and excreta comprising a bibulous material containing therein the dried residue resulting from the deposition on said material of a mixture comprising a first aqueous solution of an organic hydroperoxide, a buffer capable of maintaining the pH of the material being tested within the range of about 4 to 7, gelatin and as a fixative for said gelatin a dialdehyde polysaccharide, and a second solution of an indicator capable of being oxidized by the hydroperoxide in the presence of the prosthetic group of hemoglobin with an accompanying color change, a potentiating agent of the formula 19 R is a member selected from the group consisting of hydrogen, methyl and methoxy; R is a member selected from the group consisting of hydrogen and methyl; and R is a member selected from the group consisting of hydrogen, hydroxy, methyl and amino and an organic solvent.

12. The test indictaor of claim 11 wherein the potentiating agent is quinine.

13. The test indicator of claim 11 wherein the potentiating agent is 6-methoxyquinoline.

14. The test indicator of claim 11 wherein the potentiating agent is 6-methyl quinoline.

15. The test indicator of claim 11 wherein the potentiating agent is 7-methyl quinoline.

16. The test indicator of claim 11 wherein the potentiating agent is 4,6-dimethyl quinoline.

17. The test indicator of claim 11 wherein the potentiating agent is quinoline.

18. The test indicator of claim 11 wherein the organic hydroperoxide is a member selected from the group consisting of cumene hydroperoxide, diisopropylbenzene hydroperoxide, paramethane hydroperoxide and 2,5-dirnethylheXane-2,5-dihydroperoxide.

References Cited by the Examiner UNITED STATES PATENTS 3,012,976 12/1961 Adams et al. 252-408 3,252,762 5/1966 Adams et al. 23 -253 OTHER REFERENCES Isemura et al.: Drug and Cosmetic Industry, October 1951, p. 517.

Austin: Textile Colorist, vol. 65, No. 780, December JOSEPH SCOVRONEK, Acting Primary Examiner. Z. PAROCZAY, Assistant Examiner.

Claims (1)

11. A TEST INDICATOR FOR DETECTING OCCULT BLOOD IN BODY FLUIDS AND EXCRETA COMPRISING A BIBULOUS MATERIAL CONTAINING THEREIN THE DRIED RESIDUE RESULTING FROM THE DEPOSITION ON SAID MATERIAL OF A MIXTURE COMPRISING A FIRST AQUEOUS SOLUTION OF AN ORGANIC HYDROPEROXIDE, A BUFFER CAPABLE OF MAINTAINING THE PH OF THE MATERIAL BEING TESTED WITHIN THE RANGE OF ABOUT 4 TO 7, GALATIN AND AS A FIXATIVE FOR SAID GELATIN A DIALDEHYDE POLYSACCHARIDE, AND A SECOND SOLUTION OF AN INDICATOR CAPABLE OF BEING OXIDIZED BY THE HYDROPEROXIDE IN THE PRESENCE OF THE PROSTHETIC GROUP OF HEMOGLOBIN WITH AN ACCOMPANYING COLOR CHANGE, A POTENTIATING AGENT OF THE FORMULA
US3290117A 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent Expired - Lifetime US3290117A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3290117A US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
NL126365C NL126365C (en) 1963-06-24
US3290117A US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent
DE1964M0061333 DE1242905B (en) 1963-06-24 1964-06-11 Diagnostic agent for the detection and determination of blood, in particular for the determination of occult blood in body fluids and exudates
FR979330A FR1401656A (en) 1963-06-24 1964-06-23 sensitive compositions for the colorimetric determination of occult blood
GB2615064A GB1057056A (en) 1963-06-24 1964-06-24 Occult blood compositions using quinoline compounds for increased sensitivity
BE649682A BE649682A (en) 1963-06-24 1964-06-24
NL6407185A NL6407185A (en) 1963-06-24 1964-06-24
DK317064A DK115507B (en) 1963-06-24 1964-06-24 Composition for the detection of blood in body fluids and excrements.

Publications (1)

Publication Number Publication Date
US3290117A true US3290117A (en) 1966-12-06

Family

ID=23115165

Family Applications (1)

Application Number Title Priority Date Filing Date
US3290117A Expired - Lifetime US3290117A (en) 1963-06-24 1963-06-24 Occult blood diagnostic composition with color enhancing agent

Country Status (6)

Country Link
US (1) US3290117A (en)
BE (1) BE649682A (en)
DE (1) DE1242905B (en)
DK (1) DK115507B (en)
GB (1) GB1057056A (en)
NL (2) NL6407185A (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630847A (en) * 1967-07-20 1971-12-28 Boehringer Mannheim Gmbh Diagnostic agent for use in the determination of hydroperoxides and of peroxidate-active substances
US3853471A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic composition for the detection of peroxidatively active substances in body fluids
US3853472A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic test strip for the detection of components of body fluids
US3975161A (en) * 1975-02-14 1976-08-17 Lachema, Narodni Podnik Biological diagnostic test strip
US3986833A (en) * 1975-09-08 1976-10-19 Miles Laboratories, Inc. Test composition, device, and method for the detection of peroxidatively active substances
US4017261A (en) * 1974-10-16 1977-04-12 Lachema, Narodni Podnik Biological diagnostic test strip and method of producing same
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4189304A (en) * 1978-10-27 1980-02-19 Miles Laboratories, Inc. Device and method for detecting myoglobin
EP0014929A1 (en) * 1979-02-14 1980-09-03 Boehringer Mannheim Gmbh Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids
US4278439A (en) * 1979-12-17 1981-07-14 Miles Laboratories, Inc. Sensitizers for peroxidative activity tests
WO1982001070A1 (en) * 1980-09-24 1982-04-01 Minnesota Univ Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4539180A (en) * 1980-09-24 1985-09-03 Regents Of The University Of Minnesota Apparatus for quantitatively determining the level of hemoglobin in a biological sample
EP0184437A2 (en) * 1984-12-06 1986-06-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
WO1989005972A1 (en) * 1987-12-24 1989-06-29 Litmus Concepts, Inc. Fecal occult blood test reagents and methods
US4845030A (en) * 1984-07-09 1989-07-04 Boehringer Mannheim Gmbh Use of aniline derivates as coupling components in oxidative color formation reactions
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US4971914A (en) * 1984-12-11 1990-11-20 Litmus Concepts, Inc. Developer for fecal occult blood tests
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5068197A (en) * 1984-12-11 1991-11-26 Litmus Concepts, Inc. Fecal occult blood test methods
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US5310680A (en) * 1987-09-16 1994-05-10 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5391498A (en) * 1987-09-16 1995-02-21 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5447868A (en) * 1993-09-14 1995-09-05 Propper Manufacturing Co. Inc. Method, reagent and kit for the detection of fecal occult blood
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US20020136436A1 (en) * 2001-02-23 2002-09-26 Schrier Wayne H. Devices and methods for reading and interpreting guaiac-based occult blood tests
US20110213229A1 (en) * 2008-11-13 2011-09-01 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1143634A (en) * 1980-06-02 1983-03-29 Ann M. Tideman Interference-resistant test device for determining a peroxidately active substance in a test sample and method for preparing it
DE3716891A1 (en) * 1987-05-20 1988-12-15 Boehringer Mannheim Gmbh A test kit for determining an analyte in chair
WO1998056899A1 (en) * 1997-06-10 1998-12-17 Unilever N.V. Method for enhancing the activity of an enzyme, bleach composition, detergent composition and process for inhibiting dye transfer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012976A (en) * 1959-11-02 1961-12-12 Miles Lab Specific test composition for occult blood
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3012976A (en) * 1959-11-02 1961-12-12 Miles Lab Specific test composition for occult blood
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630847A (en) * 1967-07-20 1971-12-28 Boehringer Mannheim Gmbh Diagnostic agent for use in the determination of hydroperoxides and of peroxidate-active substances
US3853471A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic composition for the detection of peroxidatively active substances in body fluids
US3853472A (en) * 1972-07-18 1974-12-10 Boehringer Mannheim Gmbh Diagnostic test strip for the detection of components of body fluids
US4017261A (en) * 1974-10-16 1977-04-12 Lachema, Narodni Podnik Biological diagnostic test strip and method of producing same
US3975161A (en) * 1975-02-14 1976-08-17 Lachema, Narodni Podnik Biological diagnostic test strip
DE2640211A1 (en) * 1975-09-08 1977-04-07 Miles Lab substances checking means for detecting peroxidatively effective
US3986833A (en) * 1975-09-08 1976-10-19 Miles Laboratories, Inc. Test composition, device, and method for the detection of peroxidatively active substances
JPS5233594A (en) * 1975-09-08 1977-03-14 Miles Lab Testing constitutes* instruments and methods for detection of peroxidation active substances
JPS5831873B2 (en) * 1975-09-08 1983-07-08 Miles Lab
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4189304A (en) * 1978-10-27 1980-02-19 Miles Laboratories, Inc. Device and method for detecting myoglobin
US4299917A (en) * 1979-02-14 1981-11-10 Boehringer Manneheim Gmbh Diagnostic agents for the detection of leukocytes in body fluids
EP0014929A1 (en) * 1979-02-14 1980-09-03 Boehringer Mannheim Gmbh Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids
US4278439A (en) * 1979-12-17 1981-07-14 Miles Laboratories, Inc. Sensitizers for peroxidative activity tests
WO1982001070A1 (en) * 1980-09-24 1982-04-01 Minnesota Univ Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4378971A (en) * 1980-09-24 1983-04-05 Regents Of The University Of Minnesota Method and apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4539180A (en) * 1980-09-24 1985-09-03 Regents Of The University Of Minnesota Apparatus for quantitatively determining the level of hemoglobin in a biological sample
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4845030A (en) * 1984-07-09 1989-07-04 Boehringer Mannheim Gmbh Use of aniline derivates as coupling components in oxidative color formation reactions
JPH0525071B2 (en) * 1984-12-06 1993-04-09 Eastman Kodak Co
EP0184437A2 (en) * 1984-12-06 1986-06-11 EASTMAN KODAK COMPANY (a New Jersey corporation) Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes
JPS61138163A (en) * 1984-12-06 1986-06-25 Eastman Kodak Co Color developing coupler and use to measurement of hydrogen peroxide or other substance to be analyzed
EP0184437A3 (en) * 1984-12-06 1988-03-16 Eastman Kodak Company Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes
US4971914A (en) * 1984-12-11 1990-11-20 Litmus Concepts, Inc. Developer for fecal occult blood tests
US5068197A (en) * 1984-12-11 1991-11-26 Litmus Concepts, Inc. Fecal occult blood test methods
US4939097A (en) * 1986-06-02 1990-07-03 Litmus Concepts, Inc. Fecal occult blood test methods
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5391498A (en) * 1987-09-16 1995-02-21 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5310680A (en) * 1987-09-16 1994-05-10 Smithkline Diagnostics, Inc. Test for fecal occult blood
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
WO1989005972A1 (en) * 1987-12-24 1989-06-29 Litmus Concepts, Inc. Fecal occult blood test reagents and methods
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5447868A (en) * 1993-09-14 1995-09-05 Propper Manufacturing Co. Inc. Method, reagent and kit for the detection of fecal occult blood
US6410336B1 (en) 1993-09-14 2002-06-25 Propper Manufacturing Co., Ltd. Method reagent and kit for the detection of fecal occult blood
US5563071A (en) * 1993-09-14 1996-10-08 Propper Manufacturing Co., Inc. Method, reagent and kit for the detection of fecal occult blood
US6850633B2 (en) 2001-02-23 2005-02-01 Beckman Coulter, Inc. Devices and methods for reading and interpreting guaiac-based occult blood tests
US20020136436A1 (en) * 2001-02-23 2002-09-26 Schrier Wayne H. Devices and methods for reading and interpreting guaiac-based occult blood tests
US9170265B2 (en) * 2008-11-13 2015-10-27 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same
US20110213229A1 (en) * 2008-11-13 2011-09-01 Mode Diagnostics Limited Electrode, electrochemical sensor and apparatus, and methods for operating the same

Also Published As

Publication number Publication date Type
GB1057056A (en) 1967-02-01 application
BE649682A (en) 1964-10-16 grant
DE1242905B (en) 1967-06-22 application
NL6407185A (en) 1964-12-28 application
NL126365C (en) grant
DK115507B (en) 1969-10-13 grant

Similar Documents

Publication Publication Date Title
Franey et al. Serum cholesterol measurement based on ethanol extraction and ferric chloride-sulfuric acid
Ewen An improved aldehyde fuchsin staining technique for neurosecretory products in insects
Novák Colorimetric ultramicro method for the determination of free fatty acids
Gurr Synthetic dyes in biology, medicine and chemistry
Berry et al. A paper spot test useful in study of Hurler's syndrome
Brodie et al. The estimation of quinine in human plasma with a note on the estimation of quinidine
Von Euler et al. Diagnosis of pheochromocytoma by fluorimetric estimation of adrenaline and noradrenaline in urine
Brodie et al. The fate of pentobarbital in man and dog and a method for its estimation in biological material
Carpenter et al. Estimation of total cholesterol in serum by a micro method
US4997772A (en) Water-insoluble particle and immunoreactive reagent, analytical elements and methods of use
US4017261A (en) Biological diagnostic test strip and method of producing same
Sheltawy et al. Determination of faecal bile acids by an enzymic method
US5128171A (en) Method of making a test strip having a dialyzed polymer layer
Bowden et al. The application of the ceric sulphate-arsenious acid reaction to the detection of thyroxine and related substances
US5358852A (en) Use of calcium in immunoassay for measurement of C-reactive protein
US3485587A (en) Protein indicator
US3585004A (en) Test composition and device for detecting couplable compounds
US4200690A (en) Immunoassay with membrane immobilized antibody
Broughton A rapid ultraviolet spectrophotometric method for the detection, estimation and identification of barbiturates in biological material
US3406015A (en) Means for detecting the fertile period
US3630957A (en) Diagnostic agent
Dreywood Qualitative test for carbohydrate material
US4954452A (en) Non-metal colloidal particle immunoassay
US5302531A (en) Composition for the semiquantitative determination of specific gravity of a test sample
US6242207B1 (en) Diagnostic compositions and devices utilizing same